I'm curious to see if the additional cancer data impacts share price. It seems that it definitely should, but I dont recall much of a boost with the first two patients... but that could be because we were riding the Vyera deal still.

Hopefully it helps, and the good news keeps trickling in regarding the other catalysts.... $2.00 here we come!